Peces Ramón, Martínez-Ara Jorge, Peces Carlos, Picazo Mariluz, Cuesta-López Emilio, Vega Cristina, Azorín Sebastián, Selgas Rafael
Servicio de Nefrología, Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
ScientificWorldJournal. 2011 May 5;11:1041-7. doi: 10.1100/tsw.2011.94.
We report the case of a 38-year-old male with autosomal-dominant polycystic kidney disease (ADPKD) and concomitant nephrotic syndrome secondary to membranous nephropathy (MN). A 3-month course of prednisone 60 mg daily and losartan 100 mg daily resulted in resistance. Treatment with chlorambucil 0.2 mg/kg daily, low-dose prednisone, plus an angiotensin-converting enzyme inhibitor (ACEI) and an angiotensin II receptor blocker (ARB) for 6 weeks resulted in partial remission of his nephrotic syndrome for a duration of 10 months. After relapse of the nephrotic syndrome, a 13-month course of mycophenolate mofetil (MFM) 2 g daily and low-dose prednisone produced complete remission for 44 months. After a new relapse, a second 24-month course of MFM and low-dose prednisone produced partial to complete remission of proteinuria with preservation of renal function. Thirty-six months after MFM withdrawal, complete remission of nephrotic-range proteinuria was maintained and renal function was preserved. This case supports the idea that renal biopsy is needed for ADPKD patients with nephrotic-range proteinuria in order to exclude coexisting glomerular disease and for appropriate treatment/prevention of renal function deterioration. To the best of our knowledge, this is the first reported case of nephrotic syndrome due to MN in a patient with ADPKD treated with MFM, with remission of proteinuria and preservation of renal function after more than 10 years. Findings in this patient also suggest that MFM might reduce cystic cell proliferation and fibrosis, preventing progressive renal scarring with preservation of renal function.
我们报告了一例38岁男性患者,患有常染色体显性多囊肾病(ADPKD),并伴有继发于膜性肾病(MN)的肾病综合征。每日服用60毫克泼尼松和100毫克氯沙坦,疗程3个月,但治疗无效。每日服用0.2毫克/千克苯丁酸氮芥、低剂量泼尼松,加用血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体阻滞剂(ARB),治疗6周后,肾病综合征部分缓解,持续10个月。肾病综合征复发后,每日服用2克吗替麦考酚酯(MFM)和低剂量泼尼松,疗程13个月,实现了44个月的完全缓解。再次复发后,第二个疗程的MFM和低剂量泼尼松治疗24个月,使蛋白尿部分至完全缓解,同时肾功能得以保留。停用MFM 36个月后,肾病范围蛋白尿持续完全缓解,肾功能也得以保留。该病例支持这样一种观点,即ADPKD患者出现肾病范围蛋白尿时,需要进行肾活检,以排除并存的肾小球疾病,并进行适当治疗/预防肾功能恶化。据我们所知,这是首例报道的ADPKD患者因MN导致肾病综合征,使用MFM治疗后蛋白尿缓解且肾功能保留超过10年的病例。该患者的研究结果还表明,MFM可能会减少囊肿细胞增殖和纤维化,防止进行性肾瘢痕形成,同时保留肾功能。